Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 17/20 | 0.66 |
| ▸ | CNR2 | P34972 | 8/20 | 0.47 |
| ▸ | ICMT | O60725 | 1/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1993865 | 0.84 | CNR1 (0.52) | CNR1CNR2 | |
| SCHEMBL2642022 | 0.83 | CNR1 (0.57) | CNR1CNR2ICMTHRH2 | |
| SCHEMBL5566980 | 0.82 | CNR1 (0.80) | CNR1CNR2 | |
| Hydrochloric Acid SCHEMBL5644812 | 0.81 | CNR1 (0.82) | CNR1CNR2 | |
| SCHEMBL5561839 | 0.81 | CNR1 (0.98) | CNR1 | |
| SCHEMBL2659244 | 0.75 | CNR1 (0.65) | CNR1CNR2ICMT | |
| SCHEMBL2642840 | 0.75 | CNR1 (0.66) | CNR1CNR2 | |
| SCHEMBL3570810 | 0.75 | CNR1 (0.66) | CNR1CNR2 | |
| SCHEMBL7291403 | 0.74 | CNR1 (0.60) | CNR1CNR2 | |
| SCHEMBL2644061 | 0.73 | CNR1 (0.64) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700634-B2 | (Indol-3-yl) heterocycle derivatives as agonists of the cannabinoid CB1 receptor | N.V. ORGANON (NL) | 2010-04-20 | — | — | US | disclosed |
| CN-100522161-C | (indol-3-yl) -heterocyclic derivatives as agonists of the cannabinoid CB1 receptor | AKZO NOBEL NV (NL) | 2009-08-05 | — | — | CN | disclosed |
| EP-1725232-B1 | (INDOL-3-YL)-HETEROCYCLE DERIVATIVES AS AGONISTS OF THE CANNABINOID CB1 RECEPTOR | ORGANON NV (NL) | 2008-01-23 | — | — | EP | disclosed |
| US-20070142446-A1 | (Indol-3-yl) heterocycle derivatives as a agonists of the cannabinoid cb1 receptor | MERCK SHARP & DOHME B.V. (NL) | 2007-06-21 | — | — | US | disclosed |
| CN-1929836-A | (indol-3-yl) -heterocyclic derivatives as agonists of the cannabinoid CB1 receptor | AKZO NOBEL NV (NL) | 2007-03-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142446-A1 | (Indol-3-yl) heterocycle derivatives as a agonists of the cannabinoid cb1 receptor | CNR1, CNR2, OPRL1 | CNR1 1/4885CNR2 2/4885ICMT 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.